Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 15/20 | 0.65 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | GALR1 | P47211 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19336813 | 0.90 | TTK (0.65) | TTKCACNA1HMAPK1GALR1FYN | |
| SCHEMBL17445622 | 0.87 | TTK (0.78) | TTKCACNA1HFYN | |
| SCHEMBL19336826 | 0.86 | TTK (0.70) | TTKCACNA1HFYN | |
| SCHEMBL15554470 | 0.80 | TTK (1.00) | TTK | |
| SCHEMBL17445627 | 0.80 | TTK (0.66) | TTKFYN | |
| SCHEMBL19336800 | 0.79 | TTK (0.83) | TTK | |
| SCHEMBL19500853 | 0.78 | TTK (0.40) | TTK | |
| SCHEMBL17425437 | 0.75 | TTK (0.76) | TTKFYN | |
| SCHEMBL456224 | 0.74 | TTK (0.78) | TTKFYN | |
| SCHEMBL458692 | 0.73 | TTK (0.76) | TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512130-B2 | Substituted imidazopyridazines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-12-06 | — | — | US | disclosed |
| US-20160016959-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160016959-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | VEGFA, PGF, VHL | TTK 2301/4885CACNA1H 4637/4885MAPK1 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.